Ainos Expands Smell AI With Growing Real-World Scent Dataset for Physical AI
Rhea-AI Summary
Ainos (NASDAQ:AIMD) reported that its AI Nose deployments have generated approximately 613 million industrial scent data points since December 2025, mainly from semiconductor manufacturing environments. These data streams feed proprietary Smell IDs and strengthen the company’s Smell Language Model (SLM), supporting its long-term vision of a global smell intelligence network.
AI Nose digitizes scent into machine-readable Smell ID using high-precision sensor arrays and proprietary AI algorithms, targeting ppb-level sensitivity subject to deployment conditions. Offered under a SmellTech-as-a-Service subscription model, the platform is designed for continuous monitoring, predictive analysis, and real-time alerts across industrial, robotics, infrastructure, healthcare, and other physical AI applications.
Positive
- None.
Negative
- None.
News Market Reaction – AIMD
In the Jul 21 session, AIMD declined 1.89%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous AI Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 22 | Breath intelligence update | Positive | +1.1% | Research update on planned patient-level breath intelligence expansion with National Taiwan University |
| Jun 17 | Breath intelligence program | Positive | +8.5% | One-year National Taiwan University program extended Smell AI into emergency-medicine breath analysis |
| Jun 05 | Emergency department expansion | Positive | -12.6% | Research report described AI Nose expansion into live emergency-department operations |
| Jun 03 | Healthcare infrastructure study | Positive | -6.8% | Research article covered healthcare-infrastructure study deploying AI Nose in an emergency department |
| Jun 01 | Hospital AI study | Positive | -2.1% | Emergency-department study launched to model overcrowding and respiratory infection risk |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-tagged announcements showed mixed reactions, with three of five events declining and an average move of -2.37%.
Key Terms
ppb-level technical
electronic nose technical
interferon medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
AI Nose deployments have generated approximately 613 million industrial scent data points since December 2025, advancing Ainos' vision of a smell intelligence network
HOUSTON, TX / ACCESS Newswire / July 21, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer in Smell AI, today announced that its AI Nose deployments have generated approximately 613 million industrial scent data points since December 2025, primarily from semiconductor manufacturing environments.
The milestone reflects the continued expansion of Ainos' Smell AI platform. AI Nose continuously converts environmental scent patterns into machine-readable data used to create and refine proprietary Smell IDs and strengthen the Company's Smell Language Model (SLM).
"We developed Smell AI - powered by AI Nose - as a learning platform built on real-world data," said Eddy Tsai, Chairman, President and Chief Executive Officer of Ainos. "We believe every AI Nose deployment expands our proprietary scent dataset, strengthens our SLM, and advances our long-term vision of building a smell intelligence network."
Unlike conventional sensing systems that generate isolated measurements, Ainos has designed its Smell AI platform to continuously learn from and transform airborne chemical information into structured, machine-readable data that supports increasingly capable AI applications over time.
The Company's current dataset has been generated primarily from semiconductor manufacturing environments. As Ainos expands into industrial infrastructure, robotics, healthcare, and other physical AI applications, it expects the scale and diversity of its proprietary scent data to continue growing.
Ainos believes this data-driven model supports its long-term vision of a smell intelligence network, where every AI Nose deployment contributes proprietary Smell IDs that help AI systems better perceive and understand the physical world, providing a new perception layer for physical AI.
About AI Nose
AI Nose digitizes scent into Smell ID, an AI-driven form of scent intelligence. The full-stack electronic nose platform integrates high-precision sensor arrays with proprietary AI algorithms designed to support ppb-level scent detection sensitivity, subject to application conditions and deployment configurations. Smell ID converts analog scent signals into structured, actionable data, while the proprietary Smell Language Model (SLM) is designed to learn, classify, and contextualize complex scent patterns over time.
Built upon more than a decade of accumulated scent data and deep medtech expertise, AI Nose is designed to support continuous monitoring, predictive analysis, and real-time alerts across industrial and manufacturing environments. AI Nose is offered under a SmellTech-as-a-Service architecture, intended to support ongoing access to scent intelligence, analytics, and AI-driven insights through subscription-based deployment models.
About Ainos, Inc.
Ainos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date. Visit media room https://ainos.suite.accessnewswire.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Contact Information
Investor Relations
ir@ainos.com
SOURCE: Ainos, Inc.
View the original press release on ACCESS Newswire